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CHAPTER g
In chapter I au oven'ierv is gir,en of the developments in staging and treatment of lung
cancer. In chapter 2 we describe the results of staging NSCLC r.vith FDG-PET in patients
who are considered to be candidates for surgical resection of their tumour based on con-
ventional staging. We found that FDG-PET is superiol to conventional staging in detecting
mediastinal ancl distant metastases, but FDG-PET has also several l imi1.at ions. Detection
of small pulmonary nodr.rles less than 1 cm in diameter can be difficult and especiatly,'
(bronchoalveolarJ adenocarcimas may show onlv low uptake of FDG. False negative results
of FDG-PET in mediastinal lymph node staging are mostly due to micro-metastases or to
the inaltilitl' of FDG-PET to clifferentiate the plimary tumour fron.r acljacent h'n-rph node
metastases. However, due to its high negative predictive value, a FDG-PET scan wj.thout
uptake outside the primary tumciul region gives the surgeon the opportunity to proceed
directh. to a thor.acotomy, because the chance of mediastinal metastases is less than 5%.
FDG can also accumulate in benign inflammatory diseases and cause false positive results.
Therefole. we recommend that patients u,ith accumulatiotr of the tracer in the mecliastinum
should be further explored in order to find pathologic confiln-ration of malignancy. An
advantage of staging with FDG-PET is the immediate screening for distant metastases. As
FDG-PET identi f ied false posit ive sites of metastases subsequent procechrres should st i l l  be
taken to confil'm these pathologicallv. Recently, a meta-analysis alreacly suggested that
metabolic staging of the mediastinal lvmph nodes might be superior to anatomical sta-
ging. '  Although FDG-PET is expensive, i t  may be cost-effect ive when unnecessary thor.a-
cotomies can be avoidecl in case of mediastinal or distant metastases. Cost-effectiveness of
PET has alreadv been suggested. but this has not been pro\/en in cl inical studies.r 'r  Studies
are ongoing to investlgate whether implementation of FDG-PET scan can improve the
results of the diagnostic work-up in NSCLC. Till now, hardly anv data have been published
about the potential role of FDG-PET in staging of SCLC.
In patients lr- i th local ly advanced NSCLC radiotherapv has alrvays been administered.
but with rather poor lesults. In chapter 3 we describe that gemcitabine u'eekly in a dose of
300 mg/m' can be safelv combir-red with radiotherapy in these patients. This combination
rnay indr-tce a small  increase in radiat ion-induced side effects, such as racl iat ion pneumoni-
tis and esophagitis. Whether this ladiosensitising effect of gemcitabine will also improve
tumour response lates and sun,ival in these patients should be further investigated in a
randomised phase III study. Other investigatols are searching for mole effective. systemic
chemotherapy before irradiation and whethel this approach will also improve surwival.
We have also investigated the mechanism of radiosensit isat ion by gerncitabine.In chap-
ter 4 we descrlbe that in vitro non-homologous end-ioining in DNA repair is not necessa-
r1' for the racl io.sensit ising eltects rrf  gemt' i tabine. As base and nucleoticle excision repair of
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: i tabine. In chap-
ir is not necessa-
rxcision repair of
DNA are not involved in repair of DNA double-strand breaks we suggest that homologous
recombination may be the prirnarv pathway involved in the radiosensitising effect of gem-
citabine. We have started aclditional experiments in cell lines without a functional homolo-
gous recombination pathway. Tili now, these results suggest that the radiosensitising effect
of gemcitabine is indeed mediated bv homologous recombination.
In chapter 5 we describe the activitv of the combination of epirubicin and gemcitabine
in patients with metastatic NSCLC. The advantages of this schedule are that hospitallsa-
tion is not necessary and that toxicitv of cisplatin can be avoided. The combination of cis-
platin and gemcitabine has been evaluatecl in NSCLC, and several phase II and phase III
trials reported tumour response rates between 2l and 5"19lo and a median surrrival of 8,4 to
14,3 months. Whether epirubicin combinecl with gemcitabine is comparable to tire combi-
nation of cisplatin and gemcitabine in terms of sulvivai, qualitv of life and cost etfective-
ness will be furthel evaiuated in an ongoing ranciomised phase III study. Other investiga-
tors are also searching for schedules without cisplat ln, e.g. epirubicin with pacl i taxel,  gem-
citabine with docetaxel, and vinorelbine with gemcitabine. "-r Till now, randomised studies
have not shown that cisplatin can be omitted in the chemotherapeutic treatment of stage
IV NSCLC.
In chopler 6 rve found that gemcitabine as second-iine tleatment in patients who hacl
been previouslv treated for their advanced NSCLC shows onlv modest activity. Recentlv
Crino pubiished a similar study, r,l'hich shorn ed slightly better tumoru response rates ar1cl
sulvi\/al. "r Criticism to our study might especially be that there are tu'o different patient
groups; one which has been pre-treated with chemothelapy and the other with radiothera-
py. Although the last group of patients showed similar results, in general thev may be con-
sidered to be chemotherapy-nairre and not drr.rg-resistant. However, recent studies suggest
that docetaxel might be more vah-rable as second-iine tleatment after previous chemothe-
rapv. In a randomised phase III study the response rate was ioq br,rt a significant improve-
ment in survival and quality of life was sho."vn compared to best-supportlve care.l'r To defi-
ne which patient will benefit from a specific tvpe of second-line therapf in NSCLC it seems
imporlant to define as exactly as possible the plevious therapy, preyious response and time
intervai between first-line and second-line lhelapy as possible predictors for tumour
response to second-iine treatment.
The problem of drug-resistance is alreadl' known, and second-line treatment has been
further explored in SCLC. We investigated a three-drug combination in patients with resis-
tant SCLC, who progressed or relapsed shortly after first-iine treatment with CDE.We pre-
viously had shorvn promising activity of the combination of paclitaxel and carboplatin ln
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CHAPTER 9
this gror"rp of patients. We tried to improve the activi.ty of this combination by the addition
of ifosfarnide. As describecl in chapter 7 this combination increased hematological. toxicity
to such an extent that onlr' a low close of ifosfamide cor"rld be added. It is therefore not
obviotts that patients li'ill benefit from this three-drug cornbination compared to the com-
blnation of paclitaxel aud carboplatin. We decided not to investigate this combination fur-
ther. We also explored the activity of single-agent gemcitabine in these patients as is descri-
bed in chapter 8. Although this group of patients had been heavily pretreated some activi-
ty of gemcitabine was still found. As a combination of cytotoxic agents is more active in
SCLC we have recentlv started a phase II trial to studv the activity of the combination of
gemcitabine with clsplatin in patients r,,n'ith resistant SCLC.
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